Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Feb 10;28(5):780-7.
doi: 10.1200/JCO.2009.23.7537. Epub 2010 Jan 4.

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2

Jennifer L Spratlin  1 , Roger B Cohen, Matthew Eadens, Lia Gore, D Ross Camidge, Sami Diab, Stephen Leong, Cindy O'Bryant, Laura Q M Chow, Natalie J Serkova, Neal J Meropol, Nancy L Lewis, E Gabriela Chiorean, Floyd Fox, Hagop Youssoufian, Eric K Rowinsky, S Gail Eckhardt
Affiliations
Clinical Trial

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2

Jennifer L Spratlin et al. J Clin Oncol. .

Abstract

PURPOSE To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully human immunoglobulin G(1) monoclonal antibody targeting the vascular endothelial growth factor receptor (VEGFR)-2. PATIENTS AND METHODS Patients with advanced solid malignancies were treated once weekly with escalating doses of ramucirumab. Blood was sampled for PK studies throughout treatment. The effects of ramucirumab on circulating vascular endothelial growth factor-A (VEGF-A), soluble VEGFR-1 and VEGFR-2, tumor perfusion, and vascularity using dynamic contrast-enhanced magnetic resonance imaging were assessed. Results Thirty-seven patients were treated with 2 to 16 mg/kg of ramucirumab. After one patient each developed dose-limiting hypertension and deep venous thrombosis at 16 mg/kg, the next lower dose (13 mg/kg) was considered the MTD. Nausea, vomiting, headache, fatigue, and proteinuria were also noted. Four (15%) of 27 patients with measurable disease had a partial response (PR), and 11 (30%) of 37 patients had either a PR or stable disease lasting at least 6 months. PKs were characterized by dose-dependent elimination and nonlinear exposure consistent with saturable clearance. Mean trough concentrations exceeded biologically relevant target levels throughout treatment at all dose levels. Serum VEGF-A increased 1.5 to 3.5 times above pretreatment values and remained in this range throughout treatment at all dose levels. Tumor perfusion and vascularity decreased in 69% of evaluable patients. CONCLUSION Objective antitumor activity and antiangiogenic effects were observed over a wide range of dose levels, suggesting that ramucirumab may have a favorable therapeutic index in treating malignancies amenable to VEGFR-2 inhibition.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Scatterplots depicting mean values for (A) maximum concentration and (B) minimum concentration as a function of cycle number and at various ramucirumab dose levels (error bars indicate standard deviations).
Fig 2.
Fig 2.
Scatterplots depicting (A, C, and E) raw data and (B, D, and F) mean percentage changes from pretreatment values in the following pharmacodynamic assessments over time after first infusion of ramucirumab: (A and B) serum vascular endothelial growth factor (VEGF)-A; (C and D) serum soluble VEGF receptor (sVEGFR)-1; and (E and F) serum sVEGFR-2.
Fig A1.
Fig A1.
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of a target hepatic lesion (arrow) in a patient with a metastatic cholangiocarcinoma. Pretreatment imaging (A) before contrast and (B) 16 seconds after injection of gadolinium, and (C) precontrast and (D) postcontrast scans after treatment with ramucirumab 8 mg/kg in cycle 1. After ramucirumab treatment, DCE-MRI indicated notable reductions in both tumor permeability and vascularity.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Klagsbrun M, D'Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 1996;7:259–270. - PubMed
    1. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9–22. - PubMed
    1. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999;77:527–543. - PubMed
    1. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240–2245. - PubMed
    1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257. - PubMed

Publication types

MeSH terms

Substances